Marina Biotech, Inc.

As of November 15, 2016, Marina Biotech, Inc. was acquired by IthenaPharma Inc. in a reverse merger transaction. Marina Biotech, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of nucleic acid-based therapies to treat orphan diseases. The company’s therapies include small interfering RNA, microRNA (miRNA) mimics, and single stranded oligonucleotide-based compounds. Its pipeline includes CEQ508 that is in clinical development for the treatment of Familial Adenomatous Polyposis; and preclinical programs in type 1 myotonic dystrophy and Duchenne’s muscular dystrophy. The company also has a strategic alliance with Rosetta Genomics, Ltd. to identify and develop miRNA -based products to diagnose and treat various neuromuscular diseases and dystrophies; and with Avecia Nitto Denko to develop, supply, and commercialize various oligonucleotides constructs using company’s conformationally restricted nucleotide technology. It has licensing agreements with Mirna Therapeutics, Inc.; ProNAi Therapeutics, Inc.; Monsanto Company; MiNA Therapeutics, Ltd.; Novartis Institutes for Biomedical Research, Inc.; Protiva Biotherapeutics Inc.; Arcturus Therapeutics, Inc; Hongene Biotechnology; and Arbutus. The company was formerly known as MDRNA, Inc. and changed its name to Marina Biotech, Inc. in July 2010. Marina Biotech, Inc. was founded in 1983 and is based in Bothell, Washington.